Pre-market Hot Trades in US Stocks

FiEE is down 8.98% in pre-market trading. Based on recent key news:

1. On July 28, Brenmiller Energy announced that the European Investment Bank executed a waiver for the upcoming loan payment under the delayed corporate credit facility from March 2021. This news alleviated the company's short-term financial pressure but failed to boost market confidence, leading to a decline in stock price.

2. On July 28, SK Telecom is down 9.8% in pre-market trading, with the stock price falling to $31.78. Concerns about its future profitability have intensified, prompting investors to sell off shares.

3. On July 28, United Microelectronics is down 7.2% in pre-market trading, with the stock price falling to $17.71. The stock has already dropped 2% on Monday, and the consecutive two-day decline reflects the market's negative expectations regarding its performance. Overall market volatility is significant, and investor sentiment is cautious.

Carvana is down 8.78% in pre-market trading. Based on recent key news:

1. On July 29, Carvana released its second-quarter financial report, and although sales and profits hit record highs, the full-year profit guidance fell below market expectations, causing the stock price to plummet about 15% after hours.

2. On July 30, Carvana expects its full-year adjusted core profit to be between $2.7 billion and $3 billion, lower than analysts' estimate of $3 billion, further exacerbating market concerns.

3. On July 30, at least three analysts downgraded Carvana's target price, reflecting market skepticism about its profitability. The demand in the used car market remains strong, but macroeconomic impacts are significant.

Top Gainers in Pre-market US Stocks

Nuwellis is up 97.91% in pre-market trading. Based on recent key news:

1. On July 27, Nuwellis reported a preliminary revenue growth of 14% for the second quarter of 2026, driving a significant increase in stock price. The company stated that this growth was primarily due to the commercial success of the Aquadex ultrafiltration platform.

2. On July 27, Nuwellis announced a year-on-year revenue growth of 20% for the first half of 2026, further enhancing market confidence. The company plans to release its complete second-quarter financial results on August 13.

3. On July 27, Nuwellis's preliminary financial results showed significant growth momentum, attracting investor attention and driving up the stock price. The medical device industry is experiencing strong growth, capturing market interest.

T3 Defense is up 82.99% in pre-market trading. Based on recent key news:

1. On July 29, T3 Defense surged 81.56% during trading, currently reported at $23.785. This sharp increase is primarily driven by both technical and fundamental factors. The company's completed 1-for-125 reverse stock split has compressed the float to 1.12 million shares, triggering a technical short squeeze. Additionally, the company has made operational progress and achieved contract delivery in its Project 35 in the anti-drone technology field, with strategic investment news further boosting market confidence

2. On July 28, T3 Defense's subsidiary Industrial Techno-Logic Solutions completed the delivery of an automated composite production line to a major Israeli manufacturer, with a contract amount of $1.1 million. At the same time, the company holds a 60% stake in Project 35, further expanding its influence in the high-demand anti-drone technology sector. Defense investor X S.E. Security and Defense Ltd. acquired a 16.67% stake in the company in exchange for equity in Project 35, further enhancing investor interest.

3. On July 30, T3 Defense's stock reached an intraday increase of 88%, currently reported at $45.12. The stock exhibits characteristics of "small float + high trading volume," making it prone to significant fluctuations. The defense industry shows strong demand, with favorable technical indicators.

GlucoTrack pre-market rose by 49.82%. Based on recent key news:

1. On July 29, GlucoTrack's subsidiary Lōkahi Therapeutics announced the advancement of the LT-100 single-injection treatment strategy, with clinical evaluation expected in the fourth quarter of 2026. This news boosted market confidence, driving a significant increase in stock price.

2. On July 29, GlucoTrack released an announcement detailing the development progress of the LT-100 single-injection treatment, further enhancing investor expectations for the company's future development.

3. On July 28, GlucoTrack's capital structure showed its use of convertible debt and private placement financing, reflecting investors' preference for structured securities and equity-linked instruments. Despite the risks, this financing strategy provides the necessary funding support for the company. Recent changes in industry policies have led to significant capital inflows, necessitating attention to market volatility risks